{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T10:25:19Z","timestamp":1777544719758,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,10]]},"DOI":"10.7759\/cureus.52011","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T13:21:47Z","timestamp":1704892907000},"source":"Crossref","is-referenced-by-count":3,"title":["Social Interest Data as a Proxy for Off-Label Performance-Enhancing Drug Use: Implications and Clinical Considerations"],"prefix":"10.7759","author":[{"given":"Philip A","family":"Holubeck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew C","family":"Eksi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle","family":"Gillett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"O'Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J","family":"McGoldrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Demi R","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alec D","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"The coercive power of drugs in sports","author":"Murray TH","year":"2017","unstructured":"Murray TH. The coercive power of drugs in sports. The ethics of sports technologies and human enhancement. Taylor & Francis Group, Oxfordshire, United Kingdom; 2017."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0109583","article-title":"The use of google trends in health care research: a systematic review","volume":"9","author":"Nuti SV","year":"2014","unstructured":"Nuti SV, Wayda B, Ranasinghe I, Wang S, Dreyer RP, Chen SI, Murugiah K. The use of google trends in health care research: a systematic review. PLoS One. 2014, 9:e109583. 10.1371\/journal.pone.0109583","journal-title":"PLoS One"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0152802","article-title":"Analysis of the capacity of Google Trends to measure interest in conservation topics and the role of online news","volume":"11","author":"Nghiem le TP","year":"2016","unstructured":"Nghiem le TP, Papworth SK, Lim FK, Carrasco LR. Analysis of the capacity of Google Trends to measure interest in conservation topics and the role of online news. PLoS One. 2016, 11:e0152802. 10.1371\/journal.pone.0152802","journal-title":"PLoS One"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2010.02.001","article-title":"Adverse health effects of anabolic-androgenic steroids","volume":"57","author":"van Amsterdam J","year":"2010","unstructured":"van Amsterdam J, Opperhuizen A, Hartgens F. Adverse health effects of anabolic-androgenic steroids. Regul Toxicol Pharmacol. 2010, 57:117-23. 10.1016\/j.yrtph.2010.02.001","journal-title":"Regul Toxicol Pharmacol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/bjp.2008.165","article-title":"Pharmacology of anabolic steroids","volume":"154","author":"Kicman AT","year":"2008","unstructured":"Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol. 2008, 154:502-21. 10.1038\/bjp.2008.165","journal-title":"Br J Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2017.01.047","article-title":"Physiological basis behind ergogenic effects of anabolic androgens","volume":"464","author":"Cheung AS","year":"2018","unstructured":"Cheung AS, Grossmann M. Physiological basis behind ergogenic effects of anabolic androgens. Mol Cell Endocrinol. 2018, 464:14-20. 10.1016\/j.mce.2017.01.047","journal-title":"Mol Cell Endocrinol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01882","article-title":"Diagnosis and management of anabolic androgenic steroid use","volume":"104","author":"Anawalt BD","year":"2019","unstructured":"Anawalt BD. Diagnosis and management of anabolic androgenic steroid use. J Clin Endocrinol Metab. 2019, 104:2490-500. 10.1210\/jc.2018-01882","journal-title":"J Clin Endocrinol Metab"},{"key":"ref8","article-title":"Medical issues associated with anabolic steroid use: are they exaggerated?","volume":"5","author":"Hoffman JR","year":"2006","unstructured":"Hoffman JR, Ratamess NA. Medical issues associated with anabolic steroid use: are they exaggerated?. J Sports Sci Med. 2006, 5:182-93.","journal-title":"J Sports Sci Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1521-0391.2010.00059.x","article-title":"Poster abstracts from the AAAP 20th annual meeting and symposium","volume":"4","author":"McNicholas LF","year":"2010","unstructured":"McNicholas LF. Poster abstracts from the AAAP 20th annual meeting and symposium. Am J Addict. 2010, 4:368-81. 10.1111\/j.1521-0391.2010.00059.x","journal-title":"Am J Addict"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-0760(02)00220-0","article-title":"Anabolic steroids, testosterone-precursors and virilizing androgens induce distinct activation profiles of androgen responsive promoter constructs","volume":"82","author":"Holterhus PM","year":"2002","unstructured":"Holterhus PM, Piefke S, Hiort O. Anabolic steroids, testosterone-precursors and virilizing androgens induce distinct activation profiles of androgen responsive promoter constructs. J Steroid Biochem Mol Biol. 2002, 82:269-75. 10.1016\/S0960-0760(02)00220-0","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.31925\/farmacia.2018.5.3","article-title":"Selective androgen receptor modulators (SARMs) in the context of doping","volume":"66","author":"Miklos A","year":"2018","unstructured":"Miklos A, Tero-Vescan A, Vari Cu, \u0150sz Bu, Filip C, Rusz Cm, Muntean Dl. Selective androgen receptor modulators (SARMs) in the context of doping. Farmacia. 2018, 66:758-62. 10.31925\/farmacia.2018.5.3","journal-title":"Farmacia"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.sxmr.2018.09.006","article-title":"Selective androgen receptor modulators: current knowledge and clinical applications","volume":"7","author":"Solomon ZJ","year":"2019","unstructured":"Solomon ZJ, Mirabal JR, Mazur DJ, Kohn TP, Lipshultz LI, Pastuszak AW. Selective androgen receptor modulators: current knowledge and clinical applications. Sex Med Rev. 2019, 7:84-94. 10.1016\/j.sxmr.2018.09.006","journal-title":"Sex Med Rev"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.37393\/JASS.2020.02.9","article-title":"Selective androgen receptor modulators (SARM) - a new temptation in sports. Types, mode of action and side effects of their application: review","volume":"2","author":"Vasilev V","year":"2020","unstructured":"Vasilev V, Boyadjiev N. Selective androgen receptor modulators (SARM) - a new temptation in sports. Types, mode of action and side effects of their application: review. J Appl Sport Sci. 2020, 2:107-15. 10.37393\/JASS.2020.02.9","journal-title":"J Appl Sport Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41443-021-00465-0","article-title":"Adverse effects and potential benefits among selective androgen receptor modulators users: a cross-sectional survey","volume":"34","author":"Efimenko IV","year":"2022","unstructured":"Efimenko IV, Valancy D, Dubin JM, Ramasamy R. Adverse effects and potential benefits among selective androgen receptor modulators users: a cross-sectional survey. Int J Impot Res. 2022, 34:757-61. 10.1038\/s41443-021-00465-0","journal-title":"Int J Impot Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/acel.12954","article-title":"Effects of IGF-1 isoforms on muscle growth and sarcopenia","volume":"18","author":"Ascenzi F","year":"2019","unstructured":"Ascenzi F, Barberi L, Dobrowolny G, et al.. Effects of IGF-1 isoforms on muscle growth and sarcopenia. Aging Cell. 2019, 18:e12954. 10.1111\/acel.12954","journal-title":"Aging Cell"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/PL00000744","article-title":"Structure and function of the type 1 insulin-like growth factor receptor","volume":"57","author":"Adams TE","year":"2000","unstructured":"Adams TE, Epa VC, Garrett TP, Ward CW. Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci. 2000, 57:1050-93. 10.1007\/PL00000744","journal-title":"Cell Mol Life Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0954-x","article-title":"Targeting PI3K in cancer: mechanisms and advances in clinical trials","volume":"18","author":"Yang J","year":"2019","unstructured":"Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer. 2019, 18:26. 10.1186\/s12943-019-0954-x","journal-title":"Mol Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2017.06.010","article-title":"Use of growth hormone, IGF-I, and insulin for anabolic purpose: Pharmacological basis, methods of detection, and adverse effects","volume":"464","author":"Anderson LJ","year":"2018","unstructured":"Anderson LJ, Tamayose JM, Garcia JM. Use of growth hormone, IGF-I, and insulin for anabolic purpose: Pharmacological basis, methods of detection, and adverse effects. Mol Cell Endocrinol. 2018, 464:65-74. 10.1016\/j.mce.2017.06.010","journal-title":"Mol Cell Endocrinol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/00042752-200207000-00009","article-title":"Does exogenous growth hormone improve athletic performance?","volume":"12","author":"Dean H","year":"2002","unstructured":"Dean H. Does exogenous growth hormone improve athletic performance?. Clin J Sport Med. 2002, 12:250-3. 10.1097\/00042752-200207000-00009","journal-title":"Clin J Sport Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.7276","article-title":"Function of insulin-like growth factor 1 receptor in cancer resistance to chemotherapy","volume":"15","author":"Yuan J","year":"2018","unstructured":"Yuan J, Yin Z, Tao K, Wang G, Gao J. Function of insulin-like growth factor 1 receptor in cancer resistance to chemotherapy. Oncol Lett. 2018, 15:41-7. 10.3892\/ol.2017.7276","journal-title":"Oncol Lett"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00166","article-title":"Growth hormone's links to cancer","volume":"40","author":"Boguszewski CL","year":"2019","unstructured":"Boguszewski CL, Boguszewski MC. Growth hormone's links to cancer. Endocr Rev. 2019, 40:558-74. 10.1210\/er.2018-00166","journal-title":"Endocr Rev"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2017.11.057","article-title":"Potent aromatase inhibitors and molecular mechanism of inhibitory action","volume":"143","author":"Kang H","year":"2018","unstructured":"Kang H, Xiao X, Huang C, Yuan Y, Tang D, Dai X, Zeng X. Potent aromatase inhibitors and molecular mechanism of inhibitory action. Eur J Med Chem. 2018, 143:426-37. 10.1016\/j.ejmech.2017.11.057","journal-title":"Eur J Med Chem"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1210\/er.2004-0015","article-title":"Aromatase inhibitors in the treatment of breast cancer","volume":"26","author":"Brueggemeier RW","year":"2005","unstructured":"Brueggemeier RW, Hackett JC, Diaz-Cruz ES. Aromatase inhibitors in the treatment of breast cancer. Endocr Rev. 2005, 26:331-45. 10.1210\/er.2004-0015","journal-title":"Endocr Rev"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s40279-018-1014-1","article-title":"Review of WADA prohibited substances: limited evidence for performance-enhancing effects","volume":"49","author":"Heuberger JA","year":"2019","unstructured":"Heuberger JA, Cohen AF. Review of WADA prohibited substances: limited evidence for performance-enhancing effects. Sports Med. 2019, 49:525-39. 10.1007\/s40279-018-1014-1","journal-title":"Sports Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1579","article-title":"Androgen abuse in athletes: detection and consequences","volume":"95","author":"Basaria S","year":"2010","unstructured":"Basaria S. Androgen abuse in athletes: detection and consequences. J Clin Endocrinol Metab. 2010, 95:1533-43. 10.1210\/jc.2009-1579","journal-title":"J Clin Endocrinol Metab"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrfmmm.2005.02.028","article-title":"Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance","volume":"591","author":"Lewis JS","year":"2005","unstructured":"Lewis JS, Jordan VC. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat Res. 2005, 591:247-63. 10.1016\/j.mrfmmm.2005.02.028","journal-title":"Mutat Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200724050-00002","article-title":"Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development","volume":"24","author":"Gennari L","year":"2007","unstructured":"Gennari L, Merlotti D, Valleggi F, Martini G, Nuti R. Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. Drugs Aging. 2007, 24:361-79. 10.2165\/00002512-200724050-00002","journal-title":"Drugs Aging"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2008.05.010","article-title":"Male pattern baldness: current treatments, future prospects","volume":"13","author":"Ellis JA","year":"2008","unstructured":"Ellis JA, Sinclair RD. Male pattern baldness: current treatments, future prospects. Drug Discov Today. 2008, 13:791-7. 10.1016\/j.drudis.2008.05.010","journal-title":"Drug Discov Today"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.135.8.989","article-title":"Finasteride, 1 mg (Propecia), is the optimal dose for the treatment of men with male pattern hair loss","volume":"135","author":"Kaufman KD","year":"1999","unstructured":"Kaufman KD. Finasteride, 1 mg (Propecia), is the optimal dose for the treatment of men with male pattern hair loss. Arch Dermatol. 1999, 135:989-90. 10.1001\/archderm.135.8.989","journal-title":"Arch Dermatol"},{"key":"ref30","article-title":"A systematic review of topical finasteride in the treatment of androgenetic alopecia in men and women","volume":"17","author":"Lee SW","year":"2018","unstructured":"Lee SW, Juhasz M, Mobasher P, Ekelem C, Mesinkovska NA. A systematic review of topical finasteride in the treatment of androgenetic alopecia in men and women. J Drugs Dermatol. 2018, 17:457-63.","journal-title":"J Drugs Dermatol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12462307","article-title":"Mechanism of androgen action in cultured dermal papilla cells derived from human hair follicles with varying responses to androgens in vivo","volume":"98","author":"Randall VA","year":"1992","unstructured":"Randall VA, Thornton MJ, Hamada K, Messenger AG. Mechanism of androgen action in cultured dermal papilla cells derived from human hair follicles with varying responses to androgens in vivo. J Invest Dermatol. 1992, 98:86S-91S. 10.1111\/1523-1747.ep12462307","journal-title":"J Invest Dermatol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3109\/14659891.2014.911977","article-title":"A qualitative study of anabolic steroid use amongst gym users in the United Kingdom: motives, beliefs and experiences","volume":"4","author":"Kimerg\u00e5rd A","year":"201520","unstructured":"Kimerg\u00e5rd A. A qualitative study of anabolic steroid use amongst gym users in the United Kingdom: motives, beliefs and experiences. J Subst Use. 201520, 4:288-94. 10.3109\/14659891.2014.911977","journal-title":"J Subst Use"},{"key":"ref33","unstructured":"FDA In Brief. FDA warns against using SARMs in body-building products. (2017). Accessed: November 11, 2021: https:\/\/www.fda.gov\/news-events\/fda-brief\/fda-brief-fda-warns-against-using-sarms-body-building-products."},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2008.12.042","article-title":"Anabolic steroid-induced hypogonadism--towards a unified hypothesis of anabolic steroid action","volume":"72","author":"Tan RS","year":"2009","unstructured":"Tan RS, Scally MC. Anabolic steroid-induced hypogonadism--towards a unified hypothesis of anabolic steroid action. Med Hypotheses. 2009, 72:723-8. 10.1016\/j.mehy.2008.12.042","journal-title":"Med Hypotheses"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1136\/tobaccocontrol-2011-050345","article-title":"Mass media campaigns to promote smoking cessation among adults: an integrative review","volume":"21","author":"Durkin S","year":"2012","unstructured":"Durkin S, Brennan E, Wakefield M. Mass media campaigns to promote smoking cessation among adults: an integrative review. Tob Control. 2012, 21:127-38. 10.1136\/tobaccocontrol-2011-050345","journal-title":"Tob Control"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1093\/heapro\/5.1.9","article-title":"Evaluation of a mass-media campaign for the primary prevention of alcohol-related problems","volume":"5","author":"Casswell S","year":"1990","unstructured":"Casswell S, Ransom R, Gilmore L. Evaluation of a mass-media campaign for the primary prevention of alcohol-related problems. Health Promot Int. 1990, 5:9-17. 10.1093\/heapro\/5.1.9","journal-title":"Health Promot Int"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-021-06751-3","article-title":"Harm reduction in male patients actively using anabolic androgenic steroids (AAS) and performance-enhancing drugs (PEDs): a review","volume":"36","author":"Bonnecaze AK","year":"2021","unstructured":"Bonnecaze AK, O'Connor T, Burns CA. Harm reduction in male patients actively using anabolic androgenic steroids (AAS) and performance-enhancing drugs (PEDs): a review. J Gen Intern Med. 2021, 36:2055-64. 10.1007\/s11606-021-06751-3","journal-title":"J Gen Intern Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/211453-social-interest-data-as-a-proxy-for-off-label-performance-enhancing-drug-use-implications-and-clinical-considerations","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:14:21Z","timestamp":1707509661000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/211453-social-interest-data-as-a-proxy-for-off-label-performance-enhancing-drug-use-implications-and-clinical-considerations"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,10]]},"references-count":37,"URL":"https:\/\/doi.org\/10.7759\/cureus.52011","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,10]]}}}